-+ 0.00%
-+ 0.00%
-+ 0.00%

Kangfang Biotech announced that the first global phase III clinical trial of cardonilizumab compared with navulimab for first-line treatment of gastric cancer has completed the enrollment of the first patient.

Zhitongcaijing·09/28/2026 02:09:10
Listen to the news
Kangfang Biotech announced that the first global phase III clinical trial of cardonilizumab compared with navulimab for first-line treatment of gastric cancer has completed the enrollment of the first patient.